This guide is educational, not a recommendation to use TB-500 or a dosing guide. Sources checked November 2, 2026. No clinician review is claimed.
TB-500 and thymosin beta-4 are not interchangeable evidence labels. Naturally occurring, full-length thymosin beta-4 contains 43 amino acids. The TB-500 fragment evaluated by FDA is an acetylated seven-amino-acid segment, Ac-LKKTETQ. FDA also notes inconsistent commercial naming, so a product name alone does not establish its contents. A study of one molecule cannot automatically establish the benefits or safety of another. FDA scientific briefing
That distinction matters when a claim links “TB-500” to human eye-drop trials, wound research or sports recovery. Before asking whether a result is impressive, ask whether the researchers tested the same substance, by the same route, for the same problem.
Is TB-500 the same as thymosin beta-4?
In a 2012 analytical study, researchers identified Ac-LKKTETQ in a product labeled TB-500 using chromatography and mass spectrometry. This was chemical identification, not a treatment trial. It did not show that the product healed injuries, and it cannot identify the contents of every other product using that name. Esposito and colleagues, 2012
Keep these research labels separate:
- Full-length thymosin beta-4: the naturally occurring 43-amino-acid parent peptide.
- Ac-LKKTETQ: the acetylated seven-amino-acid fragment identified in the analytical TB-500 paper.
- LKKTETQ: the fragment named in an older mouse wound study; that paper's abstract does not identify it as the acetylated TB-500 product.
- NL005: a recombinant human thymosin beta-4 investigational product described as containing 44 amino acids—not the seven-amino-acid fragment.
These are distinctions reported by the FDA briefing, analytical study, mouse study and NL005 trial. Similar names are not a substitute for matching the tested molecule.
What human studies exist—and what do they show?
Eye drops: a human trial, but not an injury-recovery trial
A randomized, double-masked, placebo-controlled study enrolled 72 people with moderate-to-severe dry eye. It evaluated thymosin beta-4 ophthalmic solution, RGN-259, over 28 days. Neither primary endpoint—ocular discomfort nor inferior corneal staining at the specified assessment—showed a significant difference from placebo. Some secondary measures favored treatment. Sosne and Ousler, 2015
A fair summary includes both findings, rather than selecting only the positive outcomes. This study investigated an eye formulation and eye outcomes. It did not test TB-500 injections for tendon, muscle or joint recovery. Its results cannot answer that different clinical question. Trial methods and results
Intravenous research: early safety testing is not proof of healing
A phase I trial of recombinant NL005 enrolled 54 healthy volunteers in its single-administration component and 30 in its multiple-administration component. Researchers assessed intravenous administration, tolerability and how the investigational product behaved in the body. Reported adverse events were mild to moderate, with no serious adverse events or dose-limiting toxicity in that study. Wang and colleagues, 2021
Those findings concern the specific 44-amino-acid product, selected healthy volunteers and a short observation period. They do not establish long-term safety of the TB-500 fragment or demonstrate that it repairs an injury. “Studied in humans” needs this context to be useful. NL005 study
The fragment's clinical evidence is a different question
In its briefing for the July 2026 compounding advisory meeting, FDA reported that its literature search had not identified clinical studies of TB-500 administered to humans. This is a dated assessment—not a claim that nobody has ever used it. The later HHS policy discusses newly documented historical use, which is not the same as a randomized efficacy trial. FDA briefing, HHS policy
What does the animal wound-healing research add?
A 2003 study investigated full-thickness skin wounds in diabetic and aged mice, principally using thymosin beta-4. It also reported repair-promoting activity in aged mice for the seven-amino-acid sequence LKKTETQ. That is a preclinical observation about a specified model and peptide—not clinical proof for acetylated TB-500. Philp and colleagues, 2003
This is why “a related peptide helped wounds heal” is a starting point for research, not an answer about recovery in a person. The molecule, animal model, tissue, formulation and route must all remain attached to the finding.
Does adding TB-500 to BPC-157 have stronger evidence?
A 2026 experiment compared separate and combined treatments in 32 rats after surgically cutting and repairing an Achilles tendon. Administration was intraperitoneal—into the abdominal cavity—and assessment occurred at four weeks. The authors reported some favorable tissue and mechanical findings, but no additive effect from the combination. The abstract calls its material synthetic thymosin beta-4 or TB-500 without specifying the sequence; it should not be silently reclassified as the seven-amino-acid fragment. Biçer and colleagues, 2026
There is also a small retrospective human knee-pain report. Of 16 people reached by phone, four had received BPC-157 with a substance described as TB4, while 12 received BPC-157 alone. It was not a randomized comparison and used no standardized tools to measure functional improvement. It therefore cannot establish an added benefit from TB4, let alone prove that a specifically identified TB-500 fragment combination works. Lee and Padgett, 2021
Neither study justifies a combination protocol. For the separate evidence base, see our BPC-157 human evidence and safety guide.
Is TB-500 FDA-approved after the October 2026 policy?
No: an enforcement-discretion policy is not drug approval. The October 30 Federal Register notice describes a draft policy concerning certain section 503A compounded products while rulemaking continues. It explicitly states that compounded drugs are not FDA-approved. Federal Register notice
The associated HHS document includes TB-500 acetate for specified subcutaneous or intramuscular injectable forms subject to conditions, including qualifying analytical documentation. That is not a blanket endorsement of every product called TB-500, every route or every claimed benefit. The policy's discussion of new characterization and historical-use information should not be confused with completed clinical efficacy trials. HHS policy and appendices
Is TB-500 prohibited in sport?
WADA’s 2026 Prohibited List names thymosin beta-4 and its derivatives, including TB-500, under section S2.3. They are prohibited at all times, not only during competition. Compounding-policy changes should not be read as changes to sport rules. WADA 2026 Prohibited List
How to read the next TB-500 claim
Use these five checks when evaluating an article or study:
- Identity: Does it state the sequence or precise investigational product?
- Population: Were the participants people with the relevant condition, healthy volunteers, or animals?
- Route: Was it an eye drop, an intravenous investigational product, or something else?
- Outcome: Did the main planned outcome improve, or only selected secondary measures?
- Comparison: Was there a suitable control, and did the study actually test the claim being made?
The useful conclusion is not that all related research is worthless. It is that evidence should stay attached to what was actually studied. Keeping a personal record cannot turn an uncontrolled experience into proof that a peptide caused recovery. Jabful is a tracking app, not evidence that an experimental treatment is effective or appropriate.